Prof. Axel Ullrich: The New--Realistic--Biotech Era
Perhaps Europe's leading academic entrepreneur, professor Axel Ullrich, PhD, joined Genentech in its infancy, then, returning to Germany as a director of the Max-Planck Institute, swam against a generally anti-commercial tide within the German academic community by founding Sugen and several German start-ups, most recently, U3 Pharma. He describes the aftermath of Germany's BioRegio program and a new dose of realism in European biotech.
You may also be interested in...
The pandemic has brightened pharma’s image, but drug pricing is still high on the political agenda. For US and European politicians, the health crisis has heightened the tension between supporting innovation and controlling rising costs.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.